Skip to main content
Equibles
BPTH logo

BPTH · Bio-Path Holdings, Inc. · Metrics

Track BPTH — free

Use BPTH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BPTH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.13 -0.08 (-38.10%) At close · Feb 19 Q3 2024 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged May 20, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company’s available cash and cash equivalents of $0.1 million at March 31, 2026 will not be sufficient to fund liquidity and capital expenditure requirements for the next 12 months from the date of issuance of these consolidated financial statements. Therefore, substantial doubt exists about the Company’s ability to continue as a going concern.”
View the 10-Q filed May 20, 2026
Market Cap
$1.51M
Shares
50.30M
Volume · Feb 19 1.56M Avg daily vol (3M) 2.45M

BPTH metrics

36 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.13
Market cap
$1.51M

Price action

20 metrics
Price change (1W)
-81.9%
Price change (30D)
—
Price change (3M)
-83.5%
Price change (6M)
-91.3%
Price change (YTD)
-88.8%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
192.0%
Annualized volatility (3M)
317.2%
Beta
—
RSI (14D)
17.4
Price vs SMA 50
-84.6%
Price vs SMA 200
-90.3%
Avg volume (3M)
2.45M
Relative volume
0.6
Average dollar volume
$3.23M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
50.30M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
40.8×
reciprocal yield 2.5%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-740.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-11-15

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$10.92M
Net income (TTM)
−$11.18M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.87

Growth

11 metrics
Revenue growth YoY
+184.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$37,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+32.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-1,620.0%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$12,000
Total assets
$677,000
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$4.48M
Capital expenditures (TTM)
—
R&D (TTM)
$8.12M
SG&A (TTM)
—
Stock compensation (TTM)
$290,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1133818 CUSIP 09057N409 Visit website Investor relations